Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Early Relative Change in Hepatic Function with Lenvatinib for Unresectable Hepatocellular Carcinoma
Atsushi Hiraoka, Takashi Kumada, Masanori Atsukawa, et al.
Oncology (2019) Vol. 97, Iss. 6, pp. 334-340
Closed Access | Times Cited: 44

Showing 1-25 of 44 citing articles:

Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first‐line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study
Xiaoyan Ding, Wei Sun, Wei Li, et al.
Cancer (2021) Vol. 127, Iss. 20, pp. 3782-3793
Open Access | Times Cited: 118
The ALBI score: From liver function in patients with HCC to a general measure of liver function
Hidenori Toyoda, Philip J. Johnson
JHEP Reports (2022) Vol. 4, Iss. 10, pp. 100557-100557
Open Access | Times Cited: 88
Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience
Atsushi Hiraoka, Takashi Kumada, Toshifumi Tada, et al.
Cancer Reports (2021) Vol. 5, Iss. 2
Open Access | Times Cited: 59
Comparison of atezolizumab plus bevacizumab and lenvatinib in terms of efficacy and safety as primary systemic chemotherapy for hepatocellular carcinoma
Kazuki Maesaka, Ryotaro Sakamori, Ryoko Yamada, et al.
Hepatology Research (2022) Vol. 52, Iss. 7, pp. 630-640
Closed Access | Times Cited: 44
Lenvatinib for Hepatocellular Carcinoma: A Literature Review
Takeshi Hatanaka, Atsushi Naganuma, Satoru Kakizaki
Pharmaceuticals (2021) Vol. 14, Iss. 1, pp. 36-36
Open Access | Times Cited: 53
Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice
Yuka Hayakawa, Kaoru Tsuchiya, Masayuki Kurosaki, et al.
Investigational New Drugs (2021) Vol. 40, Iss. 2, pp. 392-402
Open Access | Times Cited: 50
Newly Developed Modified ALBI Grade Shows Better Prognostic and Predictive Value for Hepatocellular Carcinoma
Masatoshi Kudo
Liver Cancer (2021) Vol. 11, Iss. 1, pp. 1-8
Open Access | Times Cited: 44
Does first‐line treatment have prognostic impact for unresectable HCC?—Atezolizumab plus bevacizumab versus lenvatinib
Atsushi Hiraoka, Takashi Kumada, Toshifumi Tada, et al.
Cancer Medicine (2022) Vol. 12, Iss. 1, pp. 325-334
Open Access | Times Cited: 37
Sorafenib vs. Lenvatinib as First-line Therapy for Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis
Teiji Kuzuya, Masatoshi Ishigami, Takanori Ito, et al.
Anticancer Research (2020) Vol. 40, Iss. 4, pp. 2283-2290
Open Access | Times Cited: 46
Post-Progression Treatment Eligibility of Unresectable Hepatocellular Carcinoma Patients Treated with Lenvatinib
Atsushi Hiraoka, Takashi Kumada, Shinya Fukunishi, et al.
Liver Cancer (2019) Vol. 9, Iss. 1, pp. 73-83
Open Access | Times Cited: 43
Clinical importance of muscle volume in lenvatinib treatment for hepatocellular carcinoma: Analysis adjusted with inverse probability weighting
Atsushi Hiraoka, Takashi Kumada, Kazuya Kariyama, et al.
Journal of Gastroenterology and Hepatology (2020) Vol. 36, Iss. 7, pp. 1812-1819
Open Access | Times Cited: 43
Initial Experience of Ramucirumab Treatment After Lenvatinib Failure for Patients With Advanced Hepatocellular Carcinoma
Teiji Kuzuya, Masatoshi Ishigami, Takanori Ito, et al.
Anticancer Research (2020) Vol. 40, Iss. 4, pp. 2089-2093
Open Access | Times Cited: 40
Early Tumor Response and Safety of Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma in Real-World Practice
Yuwa Ando, Tomokazu Kawaoka, Masanari Kosaka, et al.
Cancers (2021) Vol. 13, Iss. 16, pp. 3958-3958
Open Access | Times Cited: 39
Comparison of the outcomes between sorafenib and lenvatinib as the first-line systemic treatment for HBV-associated hepatocellular carcinoma: a propensity score matching analysis
Na Ryung Choi, Ju Yeon Kim, Ji Hoon Hong, et al.
BMC Gastroenterology (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 23
A Multicenter Phase 2 Trial Evaluating the Efficacy and Safety of Preoperative Lenvatinib Therapy for Patients with Advanced Hepatocellular Carcinoma (LENS-HCC Trial)
Akihiko Ichida, Junichi Arita, Etsuro Hatano, et al.
Liver Cancer (2023) Vol. 13, Iss. 3, pp. 322-334
Open Access | Times Cited: 14
Early Predictors of Objective Response in Patients with Hepatocellular Carcinoma Undergoing Lenvatinib Treatment
Issei Saeki, Takahiro Yamasaki, Satoyoshi Yamashita, et al.
Cancers (2020) Vol. 12, Iss. 4, pp. 779-779
Open Access | Times Cited: 37
Prognostic Value of Changes in Combined Child–Pugh Class and ALBI Grade in Hepatocellular Carcinoma Treated with Transcatheter Intra-Arterial Therapy Plus Targeted Therapy and PD-(L)1 Inhibitors
Xiaoyu Huang, Xiaojing Cao, Yaqing Kong, et al.
Journal of Hepatocellular Carcinoma (2025) Vol. Volume 12, pp. 481-496
Open Access
Nutritional Index as Prognostic Indicator in Patients Receiving Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma
Atsushi Hiraoka, Takashi Kumada, Toshifumi Tada, et al.
Oncology (2020) Vol. 98, Iss. 5, pp. 295-302
Closed Access | Times Cited: 28
Future perspectives on immunotherapy for hepatocellular carcinoma
Landon L. Chan, Stephen L. Chan
Therapeutic Advances in Medical Oncology (2025) Vol. 17
Open Access
Systemic Treatment of Advanced Unresectable Hepatocellular Carcinoma after First-Line Therapy: Expert Recommendations from Hong Kong, Singapore, and Taiwan
Thomas Yau, David Tai, Stephen L. Chan, et al.
Liver Cancer (2022) Vol. 11, Iss. 5, pp. 426-439
Open Access | Times Cited: 16
Hypothyroidism Is a Predictive Factor for Better Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Undergoing Lenvatinib Therapy
Masako Shomura, Haruka Okabe, Emi Sato, et al.
Cancers (2020) Vol. 12, Iss. 11, pp. 3078-3078
Open Access | Times Cited: 21
Comparative Analysis of Lenvatinib and Hepatic Arterial Infusion Chemotherapy in Unresectable Hepatocellular Carcinoma: A Multi-Center, Propensity Score Study
Jaejun Lee, Ji Won Han, Pil Soo Sung, et al.
Journal of Clinical Medicine (2021) Vol. 10, Iss. 18, pp. 4045-4045
Open Access | Times Cited: 19
Portal hemodynamic effects of lenvatinib in patients with advanced hepatocellular carcinoma: A prospective cohort study
Hisashi Hidaka, Haruki Uojima, Takahide Nakazawa, et al.
Hepatology Research (2020) Vol. 50, Iss. 9, pp. 1083-1090
Closed Access | Times Cited: 20
Chronological change in serum albumin as a prognostic factor in patients with hepatocellular carcinoma treated with lenvatinib: proposal of albumin simplified grading based on the modified albumin–bilirubin score (ALBS grade)
Kazuya Kariyama, Atsushi Hiraoka, Takashi Kumada, et al.
Journal of Gastroenterology (2022) Vol. 57, Iss. 8, pp. 581-586
Closed Access | Times Cited: 12
Liver Function Changes in Patients with Hepatocellular Carcinoma Treated with Lenvatinib: Predictive Factors of Progression to Child-Pugh Class B, the Formation of Ascites and the Candidates for the Post-Progression Treatment
Takeshi Hatanaka, Satoru Kakizaki, Tamon Nagashima, et al.
Cancers (2020) Vol. 12, Iss. 10, pp. 2906-2906
Open Access | Times Cited: 18
Page 1 - Next Page

Scroll to top